ClinicalTrials.gg
CompletedNCT07942623SIGH-LPV-LIPSUpdated Nov 17, 2026

Effect of Adding Sigh Maneuver to Lung Protective Ventilation on Gas Exchange and ARDS Incidence in ARDS High-Risk ICU Patients

An interventional study of Sigh maneuver added to Lung Protective Ventilation and Lung Protective Ventilation alone in Acute Respiratory Distress Syndrome, Adult, Respiratory Insufficiency Requiring Mechanical Ventilation and Critical Illness, sponsored by Michael Humianto. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Michael Humianto · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Dec 2025, registered Nov 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Sigh maneuver is a periodic deep breath aimed at reopening collapsed alveoli. This single-center, single-blind randomized controlled trial evaluated whether adding a sigh maneuver to Lung Protective Ventilation (LPV) improves acute gas exchange and reduces the incidence of Acute Respiratory Distress Syndrome (ARDS) compared to LPV alone, in mechanically ventilated adult ICU patients at high risk of ARDS (Lung Injury Prediction Score, LIPS > 4). Fifty-two patients were randomized 1:1, stratified by baseline PF ratio, to receive either LPV with an added sigh maneuver (intermittent higher-pressure breaths via a Dräger Evita V300 ventilator) or LPV alone for 20 minutes, following a 20-minute standardization phase. The primary outcome was change in PaO2/FiO2 ratio; secondary outcomes included changes in PaO2, dynamic compliance, ventilatory ratio, PaCO2, and the incidence of ARDS (Berlin criteria) over one week of observation.

Read the detailed description

This was a single-center, single-blind, randomized controlled trial conducted in the ICU of Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Indonesia. Adult patients (18-65 years) who were intubated and mechanically ventilated for less than 24 hours, with a Lung Injury Prediction Score (LIPS) > 4 and RASS -5, were enrolled by consecutive sampling after informed consent. Exclusion criteria included pre-existing ARDS by Berlin criteria, chronic pulmonary disease, ventilator PEEP > 8 cmH2O, or refractory hemodynamic instability. After a 20-minute ventilator standardization phase (Phase 0) using a standard LPV protocol (Pressure Control-BiPAP, tidal volume 6 mL/kg predicted body weight, PEEP \<= 8 cmH2O, respiratory rate \<= 20/min, FiO2 titrated to SpO2 > 95%), patients were randomized 1:1 (stratified permuted block randomization by baseline PF ratio category) to a sigh group (LPV plus an added sigh maneuver: intermittent PEEP targeting twice the tidal volume or a peak inspiratory pressure of 30 cmH2O, once per minute, 1-3 seconds per cycle) or a control group (LPV alone) for a further 20 minutes (Phase 1). The outcome assessment team was blinded to group allocation. Arterial blood gas and ventilator parameters were recorded at the end of Phase 0 and Phase 1. Patients were then observed for up to one week (Phase 2) for the development of ARDS according to Berlin criteria. Data were analyzed on an intention-to-treat basis using SPSS version 30.

02

Conditions studied

  • Acute Respiratory Distress Syndrome, Adult
  • Respiratory Insufficiency Requiring Mechanical Ventilation
  • Critical Illness

Keywords

  • Sigh manuever
  • lung-protective ventilation
  • Lung Injury Prediction Score
  • acute respiratory distress syndrome
03

In context

Respiratory Distress Syndrome

1,388 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

This study's enrollment of 52 is below the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

This is the only study on the registry with Michael Humianto as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients aged 18-65 years with a Lung Injury Prediction Score (LIPS) > 4, intubated and mechanically ventilated for less than 24 hours since ventilation onset.
  2. Receiving analgesia, sedation, and neuromuscular blockade with a Richmond Agitation-Sedation Scale (RASS) of -5.
  3. obtained.

Exclusion criteria

Exclusion Criteria:

  1. Patients already meeting Berlin criteria for ARDS.
  2. History of chronic pulmonary disease (, asthma, other restrictive lung disease, irreversible lung disease).
  3. Ventilator PEEP setting > 8 cmH2O.
  4. Hemodynamically unstable and to vasopressor/inotropic support prior to intervention.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Sigh Manuever Group

    Received standard Lung Protective Ventilation (LPV) plus an added sigh maneuver (intermittent higher-pressure breaths, 1 cycle/min, 1-3 seconds/cycle) for 20 minutes, continued through the 1-week observation period.

    Procedure: Sigh maneuver added to Lung Protective Ventilation

  • Active comparator
    Control Group

    Received standard Lung Protective Ventilation (LPV) alone, without the sigh maneuver.

    Procedure: Lung Protective Ventilation alone

Interventions

  • ProcedureSigh maneuver added to Lung Protective Ventilation

    Intermittent higher-pressure ventilator breaths delivered via a Dräger Evita V300 ventilator, targeting twice the tidal volume or a peak inspiratory pressure of 30 cmH2O, at a frequency of 1 cycle/minute, lasting 1-3 seconds per cycle, added on top of standard LPV settings.

  • ProcedureLung Protective Ventilation alone

    Pressure Control-BiPAP ventilation with tidal volume 6 mL/kg predicted body weight, PEEP \<= 8 cmH2O, respiratory rate \<= 20/min, FiO2 titrated to SpO2 \> 95%, without the sigh maneuver feature activated.

06

What researchers measure

Primary outcomes

  1. Change in PaO2/FiO2 (P/F) ratio

    Difference in PaO2/FiO2 ratio (mmHg) between the end of the intervention phase (Phase 1, after 20 minutes of ventilation with or without sigh maneuver) and the end of the standardization phase (Phase 0). PaO2 was obtained from arterial blood gas analysis and divided by the set FiO2. A higher value indicates improved oxygenation.

    Time frame: 20 minutes

Secondary outcomes

  1. Change in PaO2

    Difference in arterial partial pressure of oxygen (PaO2, mmHg) between the end of Phase 1 and the end of Phase 0, measured by arterial blood gas analysis using a blood analyzer at the hospital clinical pathology laboratory. A higher value indicates improved oxygenation.

    Time frame: 20 minutes

  2. Change in dynamic compliance (Cdyn)

    Difference in dynamic compliance (mL/mbar) between the end of Phase 1 and the end of Phase 0. Cdyn was read from the Dräger Evita V300 ventilator display as the average of breath-by-breath values over 1 minute. A higher value indicates better lung elasticity.

    Time frame: 20 minutes

  3. Change in ventilatory ratio (VR)

    Difference in ventilatory ratio between the end of Phase 1 and the end of Phase 0. VR = (measured minute ventilation x measured PaCO2) / (predicted minute ventilation x predicted PaCO2), with predicted values based on predicted body weight (6 mL/kg tidal volume). A value near 1 indicates ventilation matching physiological needs; a value above 1 suggests increased dead space or ventilatory inefficiency. A decrease indicates improved ventilation efficiency.

    Time frame: 20 minutes

  4. Change in PaCO2

    Difference in arterial partial pressure of carbon dioxide (PaCO2, mmHg) between the end of Phase 1 and the end of Phase 0, measured by arterial blood gas analysis. PaCO2 reflects alveolar ventilation status (normal range 35-45 mmHg).

    Time frame: 20 minutes

  5. Incidence of Acute Respiratory Distress Syndrome

    Number of participants who developed ARDS during the observation period, assessed as a binary outcome (ARDS vs no ARDS). ARDS was defined by all Berlin criteria: acute onset within 7 days, bilateral opacities on chest X-ray, non-cardiogenic edema, and hypoxemia.

    Time frame: Up to 1 week

07

Study locations

1 site
  • Intensive Care Unit, Prof. Dr. I.G.N.G. Ngoerah General Hospital
    Denpasar, Bali 80114, Indonesia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Feb 2026, 2 months.

Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 2 months is below that.

Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartActual
Dec 12, 2025
Primary completionActual
Feb 28, 2026
CompletionActual
Feb 28, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942623
Lead sponsor
Michael Humianto
Collaborators
RSUP Prof. Dr. I.G.N.G. Ngoerahal
Responsible party
Michael Humianto (Physician, Anesthesiology and Intensive Care Specialist, Udayana University) — Sponsor-investigator
First posted
Nov 17, 2026
Start date
Dec 12, 2025
Primary completion
Feb 28, 2026
Completion
Feb 28, 2026
Last update
Nov 17, 2026

Study contacts

I Wayan Suranadi, Dr. dr., Sp.An-TI, Subsp.T.I.(K)
study director · Udayana University, Prof. Dr. IGNG Ngoerah General Hospital
Michael Humianto, MD, Sp.An-TI
principal investigator · Udayana University, Prof. Dr. IGNG Ngoerah General Hospital
Pontisomaya Parami, dr. Sp.An-TI, MARS, FCC
study director · Udayana University, Prof. Dr. IGNG Ngoerah General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion